Dendreon Corp fka DNDNQ

[walldiver]

DNDN Read Me First

Edits: All-cause mortality from 9901 Phase III trial presented by Dr. Eric Small at Prostate Cancer Foundation Scientific Retreat 10/20/06 (compilation of several I-Hub posts)
#msg-14152660

Notes from DNDN presentation at UBS Conference, 9/27/06, Dr. Gold presenting, courtesy of yarbonero on I-Village board
http://tinyurl.com/ftn75

Rancherho's 7/17/06 post on CD54 upgregulation, memory T-cells, and long-term survival
http://tinyurl.com/k24et

Dr. Scott Gottlieb's Feb 2005 Forbes column on Provenge; in 2/05 he was editor of a biotech newsletter, in 8/05 he became #2 at the FDA
http://tinyurl.com/43cvh

PubMed entry regarding Provenge, courtesy of thenewthinker on the Yahoo msg board
http://tinyurl.com/oavgx

PR regarding publication of the P-16 trial (Provenge+Avastin) in AIPC
http://biz.yahoo.com/prnews/060607/sfw079.html?.v=56

Several webcast presentations, including Provenge/JMP Securities/trial doctors conference call from 5/11/06
http://investor.dendreon.com/medialist.cfm

http://tinyurl.com/j9k4g
Go to: Transcript for Feb. 9, 2006
Potency Testing for Autologous Cellular Therapy
Nicole Provost PhD.
P. 131

Go to: Slides February 9,2006

From DNDN yahoo MB posted by zurdoc1...link below
http://tinyurl.com/gjnbv

spartex points out that Nicole Provost's presentation and panel questions start on page 135 in the link below.
http://tinyurl.com/fdgg8


P-11, or PROTECT Phase III for androgen-dependent prostate cancer
http://tinyurl.com/dmshb

Dr. Gold's presentation and Q&A notes at Bio-CEO conf in NYC 2/24/06
http://tinyurl.com/5hkvt
http://tinyurl.com/7w8gx
http://tinyurl.com/b6xug

9901 and 9902a Kaplan-Meier survival curves:
#msg-8677219

ECCO/Higano/9902a presentation:
http://www.sessions2view.com/ecco05c1/index.php
[Directions:
1.Click on acceptance box on bottom of screen.
2.Click on ENTER button at bottom of screen.
3. Click on Speakers link at bottom of screen.
4. Click on the letter “H” for Dr. Higano.
5. Click on one of the three icons for the slides, audio, and transcript, respectively. (The presentation audio can be cued from any individual slide.)
6. Slide #16 has the 9902a Kaplan-Meier survival curves.]

Dr. Sternberg’s 5-minute reply to Dr. Higano’s presentation:
#msg-8567652

Three most recent webcasts (10/31 conf call on Provenge 9902A trial results at ECCO, 11/4 conf call on Q3 financial results, 11/7 webcast at Rodman & Renshaw conference)
http://investor.dendreon.com/medialist.cfm

UBS 9/27/05 Conference Call Transcript and Breakout Session Notes
#msg-7922336

Dr. Eric Small presentation of 9901 trial results at May 2005 ASCO Conference
http://tinyurl.com/e2ceu

DNDN newsroom for investors
http://investor.dendreon.com/newsroom/

Discussion thread of some clinical trial summations on competitive hormone-refractory prostate cancer treatments (courtesy of rancherho)...thread continues with surrogate endpoint discussion and links
http://tinyurl.com/8syxr
http://tinyurl.com/99kfb
http://tinyurl.com/armgl
http://tinyurl.com/bnscm
http://tinyurl.com/7ozey
http://tinyurl.com/89h5p
http://tinyurl.com/ey5tf
http://tinyurl.com/99bdm

DNDN’s 9901 data-release CC (2/22/05):
http://investor.dendreon.com/medialist.cfm

ASCO Prostate Cancer presentation Dr. Eric Small 2/19/05:
http://tinyurl.com/4b7to

Provenge potential market:
http://tinyurl.com/7dwm6
http://tinyurl.com/yt9csp (“Duh, yes”)

FDA Prostate Cancer Workshop 6/04 (change to Transcript2.pdf and 3.pdf for continuation)
http://www.fda.gov/cder/drug/cancer_endpoints/ProstateTranscript1.pdf

9901 trial Gleason score breakdown (we now know that 4 out of 5 surviving placebo arm patients crossed over to receive salvage Provenge after progression)
http://tinyurl.com/5v6xy

ASCO Prostate message-board musings by walldiver (2/05)
http://tinyurl.com/5hykx
http://tinyurl.com/4ssxf

The ever-changing short-seller arguments (inspired by David Miller)
#msg-5875436

DNDN Insider Transactions
http://finance.yahoo.com/q/it?s=DNDN

Basic facts about prostate cancer
http://www.cancer.gov/cancertopics/types/prostate
http://www.acor.org/cnet/glossary/45696.html